08.03.17
Melinta Therapeutics has hired ScinoPharm to provide commercial manufacturing of delafloxacin, the active pharmaceutical ingredient (API) for Baxdela.
Baxdela is Melinta’s new drug for the treatment of acute bacterial skin and skin structure infections (ABSSSI) approved by the FDA. The API will be made at ScinoPharm’s Tainan, Taiwan facility.
“ScinoPharm is proud of the productive partnership with Melinta by being its sole API supplier of delafloxacin during Baxdela ’s launch,” said Yung Fa Chen, chief executive officer, ScinoPharm. “Beginning from process research through timely development and optimization of long and complicated synthetic routes and manufacturing processes, we have established a win-win partnership. The launching of the product will further improve our momentum in CRAM business.”
In addition to its deal with Melinta, ScinoPharm partners with other leading pharmaceutical companies for custom contract services from clinical materials to commercial supply. So far the company has handled more than 100 NCE projects, with 4 currently in phase III and 6 having already been approved for launch.
Baxdela is Melinta’s new drug for the treatment of acute bacterial skin and skin structure infections (ABSSSI) approved by the FDA. The API will be made at ScinoPharm’s Tainan, Taiwan facility.
“ScinoPharm is proud of the productive partnership with Melinta by being its sole API supplier of delafloxacin during Baxdela ’s launch,” said Yung Fa Chen, chief executive officer, ScinoPharm. “Beginning from process research through timely development and optimization of long and complicated synthetic routes and manufacturing processes, we have established a win-win partnership. The launching of the product will further improve our momentum in CRAM business.”
In addition to its deal with Melinta, ScinoPharm partners with other leading pharmaceutical companies for custom contract services from clinical materials to commercial supply. So far the company has handled more than 100 NCE projects, with 4 currently in phase III and 6 having already been approved for launch.